AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00617656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin, Docetaxel
Description: Docetaxel 75 mg/m2 and cisplatin 75 mg/m2, both on day 1, every 21 days. Total number of cycles: 6
Study NCT00617656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Cisplatin
Description: Gemcitabine 1250 mg/m2, days 1 and 8, and Cisplatin 75 mg/m2, day 1. 21-day cycles. Total number of cycles: 6
Study NCT00617656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, Cisplatin
Description: Docetaxel 75 mg/m2 and Cisplatin 75 mg/m2, both administered on day 1, every 21 days. Total number of cycles: 6
Study NCT00617656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2, day 1. 21-day cycles. Total number of cycles: 6
Study NCT03117530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Following initial baseline PET-CT imaging and clinical evaluation, adults with ASD will undergo a 12- week open-label treatment trial of minocycline to be conducted at UCLA under supervision of the UCLA IRB. During weeks 1-6, ASD subjects will be treated with 50 mg minocycline twice daily (low dose). From weeks 7-12, dosing will be increased to 100mg twice daily (typical clinical dosage). Every two weeks during this phase, a treating clinician will measure vital signs, assess safety, record adverse effects, and monitor compliance. Compliance will be obtained as an index of tolerability and will assessed through weekly medication diaries and pill counts.
Study NCT04180501 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SRS sequential sintilimab
Description: The subjects first received a targeted radiotherapy of SRS, and started the treatment of sintilimab per 3 weeks within 35 days after SRS.
Study NCT03628950 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ICSSB group
Description: At supine position with abducted limb, the probe of ultrasound will be translocated in costoclavicular space; the subclavian artery will be identified. The three cords of the brachial plexus will be visualized lateral to the artery. By using an in-plane technique and a cephalad-to-caudate direction, the block needle will be advanced until its tip will be in the middle of three cords and 10 mL of 0.25 % bupivacaine Hydrochloride will be injected. Then at lateral decubitus position, by using in-plane technique the probe will be translocated in suprascapular fossa, lateral-to-medial direction, the block needle will be advanced until its tip in the floor of the suprascapular fossa ventral to the fascia of the supraspinatus muscle and 10 mL of 0.25 % bupivacaine Hydrochloride will be injected .
Study NCT03628950 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ISB group
Description: The probe of ultrasound will be applied in lateral side of the neck at the level of the cricoid cartilage to obtain a view of the three hypoechoic structures which represent the roots of the brachial plexus. Using an in-plane technique and a lateral to-medial direction, the block needle will be advanced until its tip will be positioned under the prevertebral fascia between the two most superficial hypoechoic structures and 10 mL of 0.25 % bupivacaine Hydrochloride will be injected at level of C5-6 and another 10 ml of 0.25 % bupivacaine Hydrochloride will be injected at level of C7-8.
Study NCT02069236 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: G6PD Test
Description: All subjects are tested by multiple G6PD tests
Study NCT03033251 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non Invasive Ventilation
Description: Patients will receive non invasive ventilation as a standard of care.
Study NCT03033251 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Flow Oxygen Cannula 50
Description: Patients will receive High Flow Oxygen Cannula with a flow set at 50 L/min
Study NCT03033251 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Flow Oxygen Cannula 30
Description: Patients will receive High Flow Oxygen Cannula with a flow set at 30 L/min
Study NCT03855033 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Media Aware Sexual Health - High School
Description: Media Aware Sexual Health is a web-based comprehensive sexual health education program for high school students that uses a media literacy approach.
Study NCT03911778 — intervention group
Intervention type: OTHER
Intervention: Improvement of symptoms
Description: Improvement of symptoms on the Patient Global Impression of Improvement Index (PGI-I) scale (score 1, 2, or 3) at 6 weeks postoperatively
Study NCT01817647 — intervention group
Intervention type: PROCEDURE
Intervention: Colorectal surgery
Study NCT00589147 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Zimmer NexGen Legacy Knee System, modular cemented tibia
Description: modular cemented tibia
Study NCT00589147 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Zimmer NexGen Legacy Knee System, non-modular cemented tibia.
Description: non-modular cemented tibia.
Study NCT01195272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg iv every 4 weeks, 52 weeks
Study NCT02310243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: oral, once daily (125mg, 100mg or 75mg) for 21 days
Study NCT01411865 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toolkit
Description: Cardiovascular Disease Toolkit mailed by the Canadian Diabetes Association to family physicians, accompanying the Spring/Summer 2009 edition of the quarterly newsletter, Canadian Diabetes. (Mailed in June 2009.) The Toolkit includes a summary of selected sections of the practice guidelines targeted towards primary care physicians; a synopsis of the key messages pertaining to cardiovascular disease risk; a laminated card with a simplified algorithm for cardiovascular risk assessment and treatment; and a pad of tear-off sheets for patients with a cardiovascular risk self-assessment tool.
Study NCT01411865 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: The Spring/Summer 2009 issue of the quarterly newsletter, Canadian Diabetes, mailed on its own. The Cardiovascular Toolkit was mailed with the May 2010 issue of the newsletter.
Study NCT01826786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42165279 (100 mg)
Description: JNJ-42165279 (100 mg/day) will be orally administered once daily for 4 consecutive days.
Study NCT01826786 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to JNJ-42165279 will be orally administered once daily for 4 consecutive days.
Study NCT00777413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline 100mg Tablets
Study NCT00777413 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline 100mg Tablets
Study NCT04636359 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acupuncture stimulation
Description: The intervention is about acupuncture treatment, which has 4 weeks acupoint stimulation and the frequency is 30 minutes each times for 3 times per week. The acupoints include SJ23 (Si Zhu Kong, unilateral), GB8 (Shuai Gu, unilateral), EX-HN5 (Tai Yang, unilateral), GB20 (Feng Chi, unilateral), LI4 (He Gu, bilateral), GB41 (Zu Lin Qi, bilateral), GB34 (Yang Ling Quan, bilateral) and SJ5 (Wai Guan, bilateral).
Study NCT00281606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Different formulations of once-daily lopinavir/ritonavir
Description: CCTG585 is a randomized, open-label, two arm cross-over study to compare the tolerability of once daily LPV/r liquid versus capsules
Study NCT02159781 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: periodontal treatment - scaling and root planning
Study NCT02017860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus was provided by the investigator in 2.5 mg or 5 mg tablets for daily oral administration.
Study NCT03928353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Sodium Chloride
Description: Placebo - Sodium Chloride
Study NCT00640679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abrupt Clopidogrel Interruption
Description: Patients assigned to this group will receive Clopidogrel 75mg per day for an additional period of 4 weeks. Afterwards they will stop the drug abruptly.
Study NCT00640679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel Tapering
Description: Patients assigned to this group will have Clopidogrel gradually decreased according to a fixed tapering schema of Clopidogrel and Placebo over 4 weeks.
Study NCT00254852 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior Lateral Fusion (PLF)
Description: Posterior lateral fusion (PLF) of the lumbar spine
Study NCT00254852 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior Lumbar Interbody Fusion (ALIF)
Description: Anterior lumbar interbody fusion (ALIF)
Study NCT00254852 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transforaminal lumbar interbody fusion (TLIF)
Description: Transforaminal lumbar interbody fusion (TLIF)
Study NCT00254852 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior lumbar interbody fusion (PLIF)
Description: Posterior lumbar interbody fusion (PLIF)
Study NCT00254852 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extreme lateral interbody fusion (XLIF)
Description: Extreme lateral interbody fusion (XLIF)
Study NCT03252418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid 500 MG
Description: ascorbic acid is vitamin that can cause gingival depigmentation
Study NCT03252418 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: diode laser
Description: diode laser is soft tissue laser case photothermolysis of melanoctes
Study NCT02944188 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open right hemicolectomy plus ERAS
Description: patients treated Open right hemicolectomy plus enhanced recovery after surgery (ERAS) programs
Study NCT00589147 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Zimmer NexGen Legacy Knee System, non-modular uncemented tibia
Description: non-modular uncemented tibia
Study NCT02119026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 800mg/m2 bid d1-14~± 1000 mg/m2 bid,days 1-14 q3w: maintenance
Study NCT02119026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1000mg/m2 bid d1-14,
Study NCT02119026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 7,5 mg/kg given on d1 q3w
Study NCT02119026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 130mg/m2 iv. d 1 q3w
Study NCT02119026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 200mg/m2 iv. d 1 q3w .
Study NCT00992004 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arantal® (highly bioavailable turmeric extract)
Description: 4 capsules a day, before breakfast
Study NCT00992004 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Arantal® (highly bioavailable turmeric extract)
Description: 4 capsules a day, before breakfast
Study NCT01913860 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Improving GP antibiotics prescribing behaviour
Description: GPs will be asked to code their UTI patients within their patient management software. Anonomysed coded patients will be electronically extracted and this information will be provided as an audit and feedback report of the GPs antibiotic prescribing practices.
Study NCT01712217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT13387
Description: HSP90 inhibitor
Study NCT01712217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AT13387
Description: HSP90 inhibitor
Study NCT01712217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene1, receptor tyrosine kinase) inhibitor
Study NCT01712217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crizotinib
Description: ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene1, receptor tyrosine kinase) inhibitor
Study NCT03360045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: 500mg tranexamic acid is sprayed in the nose by atomizer spray, and then is applied nasal compression by manually.
Study NCT03360045 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 5 cc normal saline is sprayed in the nose by atomizer spray, and then is applied nasal compression by manually.
Study NCT03360045 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Merocel
Description: Merocel packing is applied.
Study NCT01224587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D1000078
Description: Oral, one single dose
Study NCT01224587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D1000082
Description: Oral, one single dose
Study NCT01224587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D1000083
Description: Oral, one single dose
Study NCT01224587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D1000085
Description: Oral, one single dose
Study NCT01383642 — intervention group
Intervention type: OTHER
Intervention: No intervention, observational study
Study NCT01148316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluoxetine
Description: drops or capsules, 10 to 80mg/Day for 14 weeks (first treatment) and as add-on to group CBT non-responders for additional 14 weeks
Study NCT01148316 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group cognitive-behavioral therapy
Description: weekly, 2 hour sessions with one therapist and one co-therapist for 14 weeks and as add-on to fluoxetine non-responders for additional 14 weeks
Study NCT03210779 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L. reuteri DSM 17938/ATCC PTA
Description: Ingestion of active lozenge twice daily for 16 days and topical application of active oil once daily for 8 days
Study NCT03210779 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ingestion of inactive lozenge twice daily for 16 days application of inactive oil once daily for 8 days
Study NCT00794014 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conservative strategy
Description: * Main vessel stenting was performed.~* Side branch ballooning and kissing ballooning were done if Thrombolysis In Myocardial Infarction (TIMI) flow \<3 in the side branch after main vessel stenting in non-left main bifurcation (non-LM) subgroup, and diameter stenosis (DS) >75% in LM subgroup.~* Side branch stenting was performed if TIMI flow \<3 in the Side branch after ballooning in non-LM subgroup, and DS >50% or dissection in the Side branch after ballooning in LM subgroup.
Study NCT00794014 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aggressive strategy
Description: * Main vessel was performed.~* Side branch ballooning and kissing ballooning were done if DS >75% in the side branch after main vessel stenting in non-LM subgroup, and DS >50% in LM subgroup.~* Side branch stenting was performed if DS >50% in the side branch after ballooning in non-LM subgroup, and DS >30% or dissection in the side branch after ballooning in LM subgroup.
Study NCT02209649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacidipine and Telmisartan fixed dose combination (FDC) tablet
Study NCT02209649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lacidipine
Study NCT02209649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Study NCT00440895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abciximab
Description: Abciximab (bolus) i.c. or i.v. or placebo, bolus dose is calculated according to current dosage (0.25 mg/kg) followed by 12 h infusion at 0.125 µg/kg/min (max 10µg/min).
Study NCT00440895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abciximab
Description: Abciximab (bolus) i.c. or i.v. or placebo, bolus dose is calculated according to current dosage (0.25 mg/kg) followed by 12 h infusion at 0.125 µg/kg/min (max 10µg/min).
Study NCT00440895 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Abciximab
Description: Abciximab (bolus) i.c. or i.v. or placebo, bolus dose is calculated according to current dosage (0.25 mg/kg) followed by 12 h infusion at 0.125 µg/kg/min (max 10µg/min).
Study NCT04325945 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low level laser therapy
Description: 808nm low level laser therapy on acupuncture points
Study NCT04325945 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Low level laser therapy
Description: 808nm low level laser therapy on acupuncture points
Study NCT00828334 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter PDA Coil
Description: The Nit-Occlud PDA is a permanently implanted prosthesis indicated for percutaneous, transcatheter closure of small to moderate size patent ductus arteriosus with a minimum angiographic diameter \< 4 mm.
Study NCT04275050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3303
Description: TQB3303 tablet is a small molecule oral drug inhibiting cyclin-dependent kinases 4 and 6 (CDK4 / 6).
Study NCT00369395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: volociximab
Description: Volociximab, 15 mg/kg, IV infusion once a week for 8 weeks. Subjects who achieved SD or better at Day 50 ± 2 days (Week 8) were eligible to continue receiving weekly infusions of volociximab until disease progression.
Study NCT00013481 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stroke Rehabilitation
Study NCT04568031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD1222
Description: For subjects in part 1 will have that route of Administration as Intramuscular, 5 × 1010 vp (nominal, ± 1.5 × 1010 vp) on V2
Study NCT01224236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Supplement
Description: 2 mg/kg/day elemental iron as multivitamin with iron solution
Study NCT01224236 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: control
Description: multivitamin solution without iron
Study NCT00570531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Pre-Operative Treatment: Bevacizumab will be given over 60-90 minutes through an I.V. catheter on days # 2 and 16. Post-Operative Treatment:Bevacizumab given over 60-90 minutes through an I.V. catheter every 21 days for 12 months, starting 6-8 weeks after surgery.
Study NCT00570531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Pre-Operative Chemotherapy treatment: Paclitaxel 45 mg/m2 will be administered as a 1-hour intravenous infusion on days #2, 9, 16, 23, and 30. It will be given before cisplatin administration.
Study NCT00570531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Pre-Operative Chemotherapy Treatment: Cisplatin 30 mg/m2 over 1 hour on days #2, 9, 16, 23, and 30. It will be given after paclitaxel.
Study NCT00570531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Pre-Operative Chemotherapy Treatment: 5-Fluorouracil at 200 mg/m2/day will be given as a continuous intravenous infusion on days #2-33.
Study NCT00570531 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Pre-Operative Treatment: Radiotherapy will be given Monday through Friday five days a week on days 1-5, 8-12, 15-19, 22-26, and 29-33. Radiotherapy will be administered using MV x-rays. CT scans, the barium swallow, the endoscopy and endoscopic ultrasound reports and PET scans should be used for tumor definition. Post-Operative Radiotherapy: In the event that gross residual disease is left behind at the time of surgery or the patient is found to have a microscopic positive deep or gastric margin following surgery, additional treatment with radiation therapy will be considered.
Study NCT00570531 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagectomy
Description: Transhiatal esophagectomy performed on approximately Day #57 (6 weeks after last dose of bevacizumab.)
Study NCT03919968 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Martial Arts
Description: The training will be performed 3 times a week, for 12 weeks, during 60 minutes, being that will be divided into 20 min of general exercises, 20 min of specific exercises and 20 min of fight simulation and / or play activities. The activities will be carried out in a way adapted for the elderly. Will be used kickers, gauntlets, thorax and head protectors, shin guards, gloves, and other devices.
Study NCT03919968 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Training
Description: The training will be performed 3 times a week, for 12 weeks, during 60 minutes, being that will be divided into 20 min of general exercises, 20 min of specific exercises and 20 min of play activities. The activities will be carried out in a way adapted for the elderly. Will be carried out neuromotor control / coordination, balance, flexibility and static and dynamic stabilization. They will also have acceleration and deceleration activities, rotation and counter-rotation, extension and counter-extension, flexion and counter-flexion.